{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:46:34Z","timestamp":1792583194320,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clml.2026.09.021","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:53:31Z","timestamp":1790870011000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Twenty-Five Years of CML Therapy in India: A Model for Precision Oncology in a Resource-Constrained Setting"],"prefix":"10.1016","author":[{"given":"Pooja","family":"Chauhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viji","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shano","family":"Naseem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6399-5257","authenticated-orcid":false,"given":"Nitya","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7688-7100","authenticated-orcid":false,"given":"Pranay","family":"Juneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charanpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Jandial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arihant","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Prinja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Khadwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.09.021_bib0001","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.clml.2026.09.021_bib0002","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.clml.2026.09.021_bib0003","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia","volume":"300","author":"de Klein","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.clml.2026.09.021_bib0004","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.09.021_bib0005","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.09.021_bib0006","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.09.021_bib0007","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s41375-026-02984-5","article-title":"From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia","volume":"40","author":"Hochhaus","year":"2026","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.09.021_bib0008","article-title":"Twenty-five years of tyrosine kinase inhibitors for chronic myeloid leukemia in Brazil","volume":"2","author":"Astigarraga","year":"2026","journal-title":"Blood Glob Hematol"},{"key":"10.1016\/j.clml.2026.09.021_bib0009","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JGO.2015.002667","article-title":"Chronic myeloid leukemia in India","volume":"3","author":"Ganesan","year":"2017","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12098-020-03234-x","article-title":"Chronic myeloid leukemia in children: challenges and opportunities","volume":"87","author":"Bansal","year":"2020","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.clml.2026.09.021_bib0011","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4103\/0971-5851.89792","article-title":"Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years (1976-2005)","volume":"32","author":"Dikshit","year":"2011","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0012","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12185-008-0230-0","article-title":"Chronic myeloid leukemia in Asia","volume":"89","author":"Au","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2026.09.021_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.580759","article-title":"Global, regional, and national burden of chronic myeloid leukemia, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"10","author":"Lin","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0014","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.09.021_bib0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/hematology.2019000050","article-title":"Meeting the needs of CML patients in resource-poor countries","volume":"2019","author":"Malhotra","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2026.09.021_bib0016","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cegh.2016.06.001","article-title":"Demographic factors related to young age at diagnosis of chronic myeloid leukemia in India","volume":"4","author":"Levine","year":"2016","journal-title":"Clin Epidemiol Glob Health"},{"issue":"suppl 8","key":"10.1016\/j.clml.2026.09.021_bib0017","article-title":"Efficacy and safety of bosutinib vs imatinib in Indian and non-Indian patients with newly diagnosed chronic phase chronic myeloid leukemia: subgroup analysis from the BELA trial","volume":"29","author":"Malhotra","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0018","first-page":"423","article-title":"Cytogenetic investigation in chronic myeloid leukemia: study from an Indian population","volume":"7","author":"Chavan","year":"2006","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clml.2026.09.021_bib0019","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.09.021_bib0020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.09.021_bib0021","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12288-018-1009-y","article-title":"Chronic myeloid leukemia: long-term outcome data in the imatinib era","volume":"35","author":"Ganesan","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2026.09.021_bib0022","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.09.021_bib0023","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.clml.2017.05.006","article-title":"Generic imatinib in chronic myeloid leukemia: survival of the cheapest","volume":"17","author":"Danthala","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.09.021_bib0024","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/0971-5851.123716","article-title":"Report of chronic myeloid leukemia in chronic phase from Tata Memorial Hospital, Mumbai, 2002-2008","volume":"34","author":"Parikh","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0025","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/jayao.2018.0007","article-title":"Adolescent and young adult chronic myeloid leukemia in real-world settings: experience from a tertiary care institute in Northern India","volume":"8","author":"Yanamandra","year":"2019","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.09.021_bib0026","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1182\/blood-2019-125978","article-title":"Long-term response evaluation of newly diagnosed chronic myeloid leukemia patients on imatinib mesylate in the Indian population over 12 years","volume":"134","author":"Rajendran","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.021_bib0027","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JGO.2015.000570","article-title":"Novel humanitarian aid program: the Glivec International Patient Assistance Program-lessons learned from providing access to breakthrough targeted oncology treatment in low- and middle-income countries","volume":"1","author":"Garcia-Gonzalez","year":"2015","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1744-8603-5-19","article-title":"Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP","volume":"5","author":"Kanavos","year":"2009","journal-title":"Global Health"},{"key":"10.1016\/j.clml.2026.09.021_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100257","article-title":"The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: the Glivec International Patient Assistance Program (GIPAP)","volume":"19","author":"Umeh","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clml.2026.09.021_bib0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12992-018-0391-4","article-title":"A pharmacovigilance system for treatment access and medical donation programs: the Max Foundation experience","volume":"14","author":"Novakowski","year":"2018","journal-title":"Global Health"},{"key":"10.1016\/j.clml.2026.09.021_bib0031","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1744-8603-10-3","article-title":"To patent or not to patent? The case of Novartis' cancer drug Glivec in India","volume":"10","author":"Gabble","year":"2014","journal-title":"Global Health"},{"key":"10.1016\/j.clml.2026.09.021_bib0032","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.mjafi.2014.07.005","article-title":"Monitoring of response to therapy with imatinib mesylate in chronic myeloid leukemia in chronic phase","volume":"70","author":"Nair","year":"2014","journal-title":"Med J Armed Forces India"},{"key":"10.1016\/j.clml.2026.09.021_bib0033","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00277-020-04289-8","article-title":"Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India","volume":"100","author":"Phukan","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.09.021_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/ijmr.ijmr_1090_21","article-title":"Feasibility of treatment-free remission with generic imatinib: results of the generic imatinib-free trial-in-chronic myeloid leukemia-chronic phase study","volume":"157","author":"Goni","year":"2023","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.clml.2026.09.021_bib0121","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.09.021_bib0122","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.09.021_bib0081","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years (STIM)","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0034","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/bloodadvances.2021004194","article-title":"Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs","volume":"5","author":"Er\u00e7al\u0131\u015fkan","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.021_bib0037","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/10428190701824585","article-title":"Imatinib mesylate in early chronic phase chronic myeloid leukemia: experience from a developing country","volume":"49","author":"Rajappa","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"suppl","key":"10.1016\/j.clml.2026.09.021_bib0041","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.clml.2015.03.014","article-title":"Factors affecting early molecular response in chronic myeloid leukemia","volume":"15","author":"Chikkodi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.09.021_bib0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0971-5851.123699","article-title":"Chronic myeloid leukemia in the imatinib era: compilation of Indian data from 22 centers involving 8115 patients (ICON)","volume":"34","author":"Parikh","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0036","first-page":"291","article-title":"Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study","volume":"53","author":"Deshmukh","year":"2005","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.clml.2026.09.021_bib0038","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/0971-5851.123728","article-title":"A short report on chronic myeloid leukemia from Post Graduate Institute of Medical Education and Research, Chandigarh","volume":"34","author":"Malhotra","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0039","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/0019-509X.134598","article-title":"Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis","volume":"51","author":"Thota","year":"2014","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.clml.2026.09.021_bib0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/0971-5851.133704","article-title":"Importance of early and deeper responses to long-term survival in CML patients: implications of BCR-ABL testing in management of CML in the Indian setting","volume":"35","author":"Agarwal","year":"2014","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0042","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.021_bib0043","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.021_bib0044","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.021_bib0046","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12962-021-00271-x","article-title":"Analysis of the gap in PCR monitoring availability for patients with chronic myeloid leukemia in 60 low- and middle-income countries","volume":"19","author":"Rowley","year":"2021","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.clml.2026.09.021_bib0047","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus Imatinib Study in Treatment-Naive CML patients","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0048","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.31357","article-title":"Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"124","author":"Naqvi","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.09.021_bib0049","article-title":"Real-world outcomes with low-dose dasatinib (50 mg) in imatinib-resistant chronic myeloid leukemia in chronic phase: a retrospective analysis of efficacy and safety","volume":"9","author":"Gangadaran","year":"2026","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.clml.2026.09.021_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2022.11.006","article-title":"Attenuated dose dasatinib in newly diagnosed chronic myeloid leukemia chronic phase patients in India","volume":"23","author":"Ahmed","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.09.021_bib0051","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1743-7563.2012.01557.x","article-title":"Dasatinib in chronic myeloid leukemia: a limited Indian experience","volume":"8","author":"Sharma","year":"2012","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0052","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12288-017-0877-x","article-title":"Experience with the use of nilotinib in Indian patients","volume":"34","author":"Manuprasad","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2026.09.021_bib0053","doi-asserted-by":"crossref","first-page":"191","DOI":"10.31557\/apjcb.2024.9.2.137-147","article-title":"A real-world analysis of safety and efficacy of nilotinib: a single-center study representing the largest cohort of Indian patients treated with nilotinib","volume":"9","author":"Kumar","year":"2024","journal-title":"Asian Pac J Cancer Biol"},{"key":"10.1016\/j.clml.2026.09.021_bib0054","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1055\/s-0041-1733301","article-title":"A retrospective cohort study of upfront nilotinib in chronic myeloid leukemia: a single-center experience","volume":"10","author":"Singh","year":"2021","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.clml.2026.09.021_bib0055","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0056","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1055\/s-0042-1756477","article-title":"The role of bosutinib in chronic myeloid leukemia: an Indian perspective","volume":"45","author":"Agarwal","year":"2024","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0057","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.021_bib0058","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0059","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3109\/10428190903332486","article-title":"Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib: mutations are rare and have different distributions","volume":"50","author":"Markose","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.09.021_bib0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4103\/0971-5851.123750","article-title":"Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate","volume":"34","author":"Rajappa","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"11","key":"10.1016\/j.clml.2026.09.021_bib0061","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.3109\/10428194.2016.1157868","article-title":"Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance","volume":"57","author":"Patkar","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.09.021_bib0062","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0042-1757911","article-title":"A retrospective analysis of BCR-ABL1 kinase domain mutations in frontline drug-intolerant or resistant chronic myeloid leukemia patients: an Indian experience from a high-end referral laboratory","volume":"13","author":"Majumdar","year":"2024","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.clml.2026.09.021_bib0063","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12288-024-01769-z","article-title":"A retrospective analysis of BCR-ABL-1 kinase domain mutations in frontline TKI resistant chronic myeloid leukemia patients: a single centre experience","volume":"40","author":"Datta","year":"2024","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2026.09.021_bib0064","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/jpgm.JPGM_781_20","article-title":"Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: a single center experience","volume":"68","author":"Bommannan","year":"2022","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.clml.2026.09.021_bib0065","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/ajh.27037","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era","volume":"98","author":"Haddad","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.09.021_bib0066","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.09.021_bib0067","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1007\/s13277-014-1926-9","article-title":"Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India","volume":"35","author":"Kagita","year":"2014","journal-title":"Tumor Biol"},{"key":"10.1016\/j.clml.2026.09.021_bib0068","article-title":"BCR-ABL kinase domain mutations in CML patients: experience from a tertiary care center in North India","volume":"21","author":"Akhilesh","year":"2024","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.clml.2026.09.021_bib0069","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.09.021_bib0070","first-page":"2503","article-title":"Ponatinib in the management of chronic myeloid leukemia: an Indian real-world experience and its toxicity profile","volume":"62","author":"Jandial","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.09.021_bib0071","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs (ASCEMBL)","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.021_bib0072","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/sj.bmt.1702869","article-title":"Allogeneic bone marrow transplantation in the developing world: experience from a center in India","volume":"27","author":"Chandy","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.09.021_bib0073","first-page":"71","article-title":"Allogeneic blood stem cell transplantation in chronic myeloid leukemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report","volume":"17","author":"Saikia","year":"2004","journal-title":"Natl Med J India"},{"key":"10.1016\/j.clml.2026.09.021_bib0074","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.bmt.1704107","article-title":"Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia","volume":"32","author":"Das","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.09.021_bib0075","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/0971-5851.142036","article-title":"Current status of hematopoietic stem cell transplant in chronic myeloid leukemia","volume":"35","author":"Gupta","year":"2014","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0076","first-page":"89","article-title":"Outcomes of allogeneic stem cell transplant in chronic myeloid leukemia-blast phase: a single-center experience from South India","volume":"43","author":"Nakka","year":"2022","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0077","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1007\/s00277-025-06350-w","article-title":"Allogeneic transplantation for CML blast phase: learnings over last decade from a single center in North India","volume":"104","author":"Patra","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.09.021_bib0078","doi-asserted-by":"crossref","first-page":"23","DOI":"10.25259\/IJMIO_15_2024","article-title":"Role of stem cell transplant in chronic myeloid leukemia in contemporary settings","volume":"10","author":"Chichra","year":"2025","journal-title":"Int J Mol Immuno Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.021_bib0082","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised trial","volume":"19","author":"Sau\u00dfele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2026.09.021_bib0083","article-title":"Can imatinib be stopped based on complete cytogenetic response in chronic phase CML: experience from a single institution from India","volume":"29","author":"Cyriac","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0084","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s12288-024-01777-z","article-title":"Real world outcomes with treatment-free remission in chronic myeloid leukemia: experience from a tertiary care cancer center","volume":"40","author":"Sarma","year":"2024","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2026.09.021_bib0085","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41408-025-01390-x","article-title":"Treatment free remission (TFR) in chronic myeloid leukemia\u2014results, compliance and patterns of failure from a tertiary care cancer centre in India","volume":"15","author":"Punatar","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.09.021_bib0086","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ajh.27528","article-title":"Treatment-free remissions in children with chronic myeloid leukemia (CML): a prospective study from the Tata Memorial Hospital (TMH) pediatric CML (pCML) cohort","volume":"100","author":"Roy Moulik","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.09.021_bib0087","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2518028","article-title":"Treatment-free remission in chronic myeloid leukemia in low- and middle-income countries [letter]","author":"Annamalay","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.09.021_bib0088","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.09.021_bib0089","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.09.021_bib0090","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1182\/bloodadvances.2020003235","article-title":"Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel","volume":"5","author":"Pavlovsky","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.021_bib0091","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.021_bib0092","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s12288-024-01743-9","article-title":"Maternal and foetal outcomes of newly diagnosed chronic myeloid leukemia during pregnancy and its long-term impact","volume":"40","author":"Bhattacharjee","year":"2024","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2026.09.021_bib0093","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1093\/annonc\/mdi398","article-title":"Pregnancy outcome of two patients treated with imatinib","volume":"16","author":"Prabhash","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0094","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/annonc\/mdj065","article-title":"Pregnancy on imatinib: fatal outcome with meningocele","volume":"17","author":"Choudhary","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0095","first-page":"1","article-title":"Pregnancy outcomes in chronic myeloid leukemia: a single-center experience from India","volume":"5","author":"Madabhavi","year":"2019","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0096","first-page":"456","article-title":"Pregnancy outcome in chronic myeloid leukemia patients on planned imatinib therapy: a prospective study from eastern India","volume":"31","author":"Mukhopadhyay","year":"2015","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2026.09.021_bib0097","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00277-023-05280-9","article-title":"Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution","volume":"102","author":"Chethan","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.09.021_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107367","article-title":"Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies","volume":"133","author":"Bhattacharjee","year":"2023","journal-title":"Leuk Res"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.09.021_bib0099","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2025-2009","article-title":"IMPACT-CML: Indian multicentric data supporting safe pregnancy and molecular control in women with chronic myeloid leukemia","volume":"146","author":"Singh","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.021_bib0101","article-title":"Pregnancy management in CML patients: to treat or not to treat? Report of 224 outcomes","volume":"15","author":"Abruzzese","year":"2023","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2026.09.021_bib0100","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.24186","article-title":"The impact of dasatinib on pregnancy outcomes","volume":"90","author":"Cortes","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.09.021_bib0102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12288-024-01930-8","article-title":"Management of CML and pregnancy in low- and middle-income countries","volume":"41","author":"Malhotra","year":"2025","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2026.09.021_bib0103","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12288-024-01846-3","article-title":"Effect of imatinib on ovarian reserve in women with chronic myeloid leukemia: a case-control study","volume":"41","author":"Suri","year":"2025","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2026.09.021_bib0104","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s12288-024-01932-6","article-title":"Impact of dasatinib on female reproductive health in Philadelphia-positive leukemia patients","volume":"41","author":"Kintada","year":"2025","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"suppl","key":"10.1016\/j.clml.2026.09.021_bib0105","article-title":"Treatment and outcome of chronic myeloid leukemia in children and adolescents: the Indian Pediatric Oncology Group (INPOG-CML-16-01) multicentric study","volume":"66","author":"Totadri","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2026.09.021_bib0106","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12288-015-0621-3","article-title":"CML as part of dual malignancies\u2014a retrospective analysis: possible mechanisms and review of literature","volume":"32","author":"Sahu","year":"2016","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2026.09.021_bib0107","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s12288-024-01797-9","article-title":"Imatinib mesylate causes potential cardiac dysfunction in patients with chronic myeloid leukemia: results of a case-control study","volume":"40","author":"Shankar","year":"2024","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2026.09.021_bib0108","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/ijd.13852","article-title":"Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients","volume":"57","author":"Vinay","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clml.2026.09.021_bib0109","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12288-015-0612-4","article-title":"Audiovestibular status in CML patients on imatinib mesylate with review of literature","volume":"33","author":"Gupta","year":"2017","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2026.09.021_bib0110","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.09.021_bib0111","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/jcm10030515","article-title":"Dose optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: a new therapeutic challenge","volume":"10","author":"Iurlo","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2026.09.021_bib0112","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.021_bib0113","doi-asserted-by":"crossref","first-page":"68","DOI":"10.25259\/IJMIO_14_2024","article-title":"The cost-effectiveness of chronic myeloid leukemia treatment strategies in the Indian healthcare context","volume":"9","author":"Jain","year":"2024","journal-title":"Int J Mol Immuno Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0114","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1065737","article-title":"Financial toxicity of cancer treatment in India: towards closing the cancer care gap","volume":"11","author":"Prinja","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.clml.2026.09.021_bib0115","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clml.2016.02.040","article-title":"Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib","volume":"16","author":"Unnikrishnan","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.09.021_bib0116","first-page":"1","article-title":"Variation in adherence measures to imatinib therapy","volume":"4","author":"Yanamandra","year":"2018","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.clml.2026.09.021_bib0117","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2015.013","article-title":"Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study","volume":"7","author":"Kapoor","year":"2015","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2026.09.021_bib0118","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia (ASC4FIRST)","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.09.021_bib0119","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.09.021_bib0120","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2023-181369","article-title":"Outcomes in young CML treated with TKI: registry data from the Hematological Cancer Consortium (HCC) of India","volume":"142","author":"Kapoor","year":"2023","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026039923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026039923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:29:37Z","timestamp":1792582177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026039923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":121,"alternative-id":["S2152265026039923"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twenty-Five Years of CML Therapy in India: A Model for Precision Oncology in a Resource-Constrained Setting","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}